Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
190.5 USD | -0.85% | -6.46% | -26.37% |
01:28pm | Oppenheimer Adjusts Biogen Price Target to $270 From $290 | MT |
Apr. 17 | UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.37% | 27.69B | |
-5.99% | 84.46B | |
+3.95% | 40.85B | |
+52.09% | 24.28B | |
-6.59% | 17.09B | |
-32.37% | 13.67B | |
-10.45% | 11.79B | |
-15.88% | 11.86B | |
-3.00% | 8.07B | |
+0.53% | 7.51B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen, Ionis Pharmaceuticals Discontinue Clinical Program for Amyotrophic Lateral Sclerosis Treatment; Shares Fall